Hannah Jewell writes The 7, The Washington Post’s morning briefing, which is available each weekday from 7 a.m. to 10 a.m. Eastern time on mobile, desktop and inboxes. She is also the host of ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Alison Sweeney’s new movie, Reality Bites: A Hannah Swensen Mystery, will premiere on Thursday, February 6, on Hallmark Mystery. In the sixth installment of the series, Sweeney is not only ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

Hannah Natanson is a reporter covering national education. She won a Peabody in 2024 for a podcast series on school gun violence. She was part of a team of Post journalists awarded the 2022 ...

"She cares about people, and it shows up in her work." Award-winning journalist Hannah McDonald is a general assignment reporter at NewsChannel 5 Nashville. Hannah is the 2024 recipient of the ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77% ...